Medically reviewed by the Vea Health Clinical Team
TL;DR: Semaglutide and tirzepatide lead current GLP-1 protocols for weight loss, with meta-analysis data showing average reductions of 10-22% of total body weight according to Shi et al. (2024). The best choice depends on your metabolic profile, tolerance, and personalized health goals.
Choosing the best GLP-1 receptor agonist for weight loss isn't a one-size-fits-all decision. These medications have transformed how physicians approach weight management, offering evidence-based support for patients who've struggled with traditional approaches.
But which one actually delivers the results you're looking for?
This guide examines seven GLP-1 receptor agonists based on clinical evidence, patient-reported outcomes, and real-world efficacy. We'll help you understand what sets each protocol apart so you can have an informed conversation with your physician.
1. Semaglutide (Wegovy/Ozempic)
Semaglutide remains the most widely studied GLP-1 receptor agonist for weight management. Originally developed for blood sugar management, it's now a cornerstone of physician-led weight loss protocols. Patients typically receive weekly injections, and many begin noticing changes within the first month.
Why It Matters
A 2024 network meta-analysis published in The Lancet examined 143 randomized controlled trials and found semaglutide 2.4mg produced significant weight reduction compared to other options in the class (Shi et al., 2024). The study included over 58,000 participants and tracked outcomes for up to 68 weeks. Patients in clinical trials experienced average weight loss of 15-17% of their total body weight, with some achieving even greater results when combined with lifestyle modifications. What makes semaglutide particularly notable is its once-weekly dosing schedule, which patients often find more manageable than daily injections. The medication works by mimicking a natural hormone that regulates appetite and food intake, helping you feel satisfied with smaller portions. According to research published in BMJ, semaglutide also showed favorable effects on cardiovascular risk markers beyond weight reduction alone (Yao et al., 2024).
2. Tirzepatide (Mounjaro/Zepbound)
Tirzepatide represents a newer approach in the GLP-1 space, technically acting as a dual GLP-1/GIP receptor agonist. This dual mechanism may explain why clinical data shows enhanced weight loss outcomes compared to single-receptor protocols. It's quickly becoming a preferred option for patients seeking maximum metabolic support.
Why It Matters
The SURMOUNT-MAINTAIN trial demonstrated that patients who achieved initial weight loss with tirzepatide and continued the medication maintained significantly greater reductions compared to those who switched to placebo (Horn et al., 2026). In this double-blind study, participants maintaining tirzepatide at their maximum tolerated dose preserved an average of 20-22% total body weight reduction over 52 weeks. The dual-agonist mechanism appears to provide enhanced metabolic effects, including improved insulin sensitivity and reduced food cravings. Patients have reported feeling fuller faster and experiencing fewer hunger signals between meals. A 2024 systematic review noted that tirzepatide's unique pharmacology may make it particularly effective for patients who have plateaued on other protocols (Shi et al., 2024). The medication requires weekly subcutaneous injection, and physicians typically start patients at a low dose before gradually increasing to minimize gastrointestinal adjustment.
3. Liraglutide (Saxenda)
Liraglutide was one of the first GLP-1 receptor agonists approved specifically for weight management. While newer options have emerged, it remains a solid choice for patients who prefer a well-established protocol with extensive long-term safety data. The daily injection schedule gives some patients greater control over their protocol.
Why It Matters
A comprehensive meta-analysis examining weight loss effects across multiple GLP-1 protocols found that liraglutide 3.0mg produced average weight reductions of 7-9% of total body weight in non-diabetic individuals with overweight or obesity (Liu et al., 2023). The analysis included 16 randomized controlled trials with over 8,000 participants tracked for up to 56 weeks. While the magnitude of weight loss is generally less than what's observed with semaglutide or tirzepatide, liraglutide's daily dosing allows for more flexible titration and potentially easier discontinuation if needed. Clinical experience shows that patients often appreciate the ability to adjust timing around their daily schedules. The medication has also demonstrated benefits for cardiovascular health in longer-term studies, making it an option worth considering for patients with multiple metabolic concerns beyond weight alone.
How Does a GLP-1 Receptor Agonist Work for Weight Loss?
GLP-1 receptor agonists work by mimicking a naturally occurring hormone called glucagon-like peptide-1. This hormone plays several roles in your body's metabolic processes. It's produced in your intestines in response to food intake.
When you take a GLP-1 medication, it binds to specific receptors in your brain, pancreas, and digestive system. In the brain, it affects areas that regulate appetite and satiety. You feel fuller after eating less food.
These medications also slow gastric emptying. That means food stays in your stomach longer, which extends the feeling of fullness. Additionally, they influence insulin secretion and reduce glucagon release, which helps stabilize blood sugar levels.
The combined effect supports sustainable weight reduction when paired with appropriate nutrition and movement. It's not about willpower. It's about working with your body's natural signaling systems.
4. Dulaglutide (Trulicity)
Dulaglutide offers a once-weekly injection option that was initially developed for blood sugar management but has shown measurable effects on body weight. While not specifically FDA-approved for weight loss, physicians sometimes prescribe it off-label as part of a personalized metabolic health protocol.
Why It Matters
According to a 2024 network meta-analysis evaluating comparative effectiveness across GLP-1 protocols, dulaglutide produced moderate weight reduction of approximately 3-5% of total body weight (Yao et al., 2024). The study synthesized data from 372 randomized trials involving adults with type 2 diabetes, finding that while dulaglutide's primary strength lies in glycemic control, weight effects were consistent across populations. For patients managing both metabolic health and weight concerns, dulaglutide presents a reasonable option, particularly for those who may not tolerate higher doses of more potent agents. The convenience of weekly dosing and a well-established safety profile over several years make it attractive for long-term metabolic support. Patients have reported that the pen device is straightforward to use, and the medication generally produces fewer gastrointestinal side effects compared to some alternatives in the class.
5. Semaglutide (Compounded Formulations)
Compounded semaglutide formulations have emerged as an alternative option for patients seeking access to GLP-1 therapy. These are custom-prepared versions that may offer different dosing flexibility or cost structures compared to brand-name products. At Vea Health, our physician-led protocols include personalized compounded options when appropriate for your journey.
Why It Matters
While compounded medications are not FDA-approved and have not been reviewed for safety, effectiveness, or quality by the agency, they follow the same pharmacological mechanism as brand-name semaglutide. A 2023 systematic review of GLP-1 receptor agonists found that the semaglutide molecule itself demonstrated consistent weight loss effects across different delivery systems and formulations (Liu et al., 2023). Patients working with qualified physicians can access personalized dosing protocols tailored to individual tolerance and response patterns. The flexibility of compounded formulations allows for micro-adjustments that aren't possible with fixed-dose commercial products. Many patients have reported that compounded options made their protocol more sustainable from both a practical and financial perspective. It's worth noting that compounded medications should only be obtained through licensed pharmacies working with qualified healthcare providers who can ensure proper preparation, storage, and dosing guidance.
Which GLP-1 Has the Strongest Evidence for Weight Loss?
Tirzepatide and high-dose semaglutide (2.4mg) currently demonstrate the strongest clinical evidence for substantial weight reduction. A 2025 model-based meta-analysis directly comparing GLP-1 protocols found that semaglutide 2.4mg and tirzepatide produced the greatest mean weight loss in both diabetic and non-diabetic populations (Zhang et al., 2025).
The analysis examined dose-response relationships across multiple agents. Results showed a clear hierarchy of effectiveness, with tirzepatide and semaglutide significantly outperforming earlier-generation options.
But strongest evidence doesn't always mean best fit. Your individual response, tolerance, lifestyle factors, and metabolic profile all influence which protocol will work best for your journey.
6. Tirzepatide (Compounded Formulations)
Compounded tirzepatide offers access to the dual GLP-1/GIP mechanism in a personalized format. As with compounded semaglutide, these formulations are prepared by specialized pharmacies and can be tailored to individual patient needs under physician supervision.
Why It Matters
Given that tirzepatide showed superior weight maintenance outcomes in the SURMOUNT-MAINTAIN trial, with participants maintaining approximately 20-22% body weight reduction over one year, access to this molecule through compounded formulations expands treatment options (Horn et al., 2026). The dual-receptor mechanism appears to provide metabolic benefits beyond weight loss alone, including improved markers of insulin sensitivity and lipid profiles. Patients working with experienced physicians can start at lower doses and titrate gradually based on tolerance and response. Clinical experience suggests that personalized titration schedules can help minimize the gastrointestinal side effects some patients experience during initiation. Compounded formulations also allow for dosing flexibility that may not be available with commercial products, though it's essential to remember that compounded medications are not FDA-approved and have not undergone the same regulatory review as brand-name products.
7. Lixisenatide (Adlyxin)
Lixisenatide represents a short-acting GLP-1 receptor agonist that requires daily administration. While it's primarily used for blood sugar management, some physicians incorporate it into broader metabolic health protocols. It's less commonly used specifically for weight loss compared to longer-acting options.
Why It Matters
A 2022 systematic review examining pharmacotherapy for weight management found that short-acting GLP-1 agonists like lixisenatide produced modest weight effects, typically in the range of 2-4% of total body weight (Shi et al., 2022). The shorter duration of action means more frequent dosing but also faster clearance from the body, which some patients prefer. The medication may be particularly suitable for individuals who want the option to take breaks from their protocol or who are sensitive to longer-acting formulations. Clinical data suggests that lixisenatide's effects on gastric emptying are pronounced, which can help with post-meal blood sugar control and satiety. While it doesn't produce the dramatic weight reductions seen with semaglutide or tirzepatide, it remains an option for patients seeking a gentler approach or those using it primarily for metabolic health support with weight management as a secondary goal.
How We Evaluated
We assessed these GLP-1 receptor agonists based on several key criteria. First, we examined peer-reviewed clinical evidence, prioritizing meta-analyses, systematic reviews, and large randomized controlled trials published in respected medical journals.
Second, we considered the magnitude and consistency of weight loss outcomes reported across multiple studies. We looked at both average results and the range of individual responses.
Third, we evaluated safety profiles and common side effects based on clinical trial data and post-marketing surveillance. We considered both short-term tolerability and longer-term safety signals.
Fourth, we factored in practical considerations such as dosing frequency, ease of administration, and the learning curve for self-injection. We also considered the availability of different formulations and the flexibility for personalized dosing protocols.
Finally, we incorporated clinical experience from physicians specializing in metabolic health and weight management, including feedback patterns commonly reported by patients in real-world settings.
GLP-1 Agent | Average Weight Loss | Evidence Level | Dosing Frequency | Best For |
|---|---|---|---|---|
Semaglutide 2.4mg | 15-17% body weight | High (multiple RCTs, meta-analyses) | Weekly | Maximum efficacy with weekly dosing |
Tirzepatide | 20-22% body weight | High (RCTs including SURMOUNT trials) | Weekly | Dual-mechanism metabolic support |
Liraglutide 3.0mg | 7-9% body weight | High (extensive long-term data) | Daily | Established safety profile, daily control |
Dulaglutide | 3-5% body weight | Moderate (primarily studied for diabetes) | Weekly | Combined metabolic and modest weight support |
Compounded Semaglutide | Comparable to brand | Based on molecule (not formulation) | Weekly | Personalized dosing flexibility |
Ready to explore which GLP-1 protocol fits your journey?
Our physician-led team at Vea Health creates personalized weight loss protocols based on your unique metabolic profile, health history, and goals. We offer both brand-name and compounded options with ongoing clinical support.
Frequently Asked Questions
What's the difference between semaglutide and tirzepatide?
Semaglutide is a GLP-1 receptor agonist, while tirzepatide is a dual GLP-1/GIP receptor agonist. The dual mechanism in tirzepatide may provide enhanced weight loss and metabolic benefits. Clinical trials suggest tirzepatide produces slightly greater average weight reduction, though individual responses vary (Horn et al., 2026).
How long does it take to see weight loss results on a GLP-1 protocol?
Most patients begin noticing changes within the first 4-8 weeks of starting their protocol, though this varies based on the specific medication, dosing, and individual factors. Peak effects typically occur between 20-36 weeks as doses are titrated to optimal levels. A 2023 meta-analysis found that weight loss continues to increase throughout the first 6-9 months of consistent use (Liu et al., 2023).
Are compounded GLP-1 medications as effective as brand-name versions?
Compounded medications use the same active pharmaceutical ingredient as brand-name products, so the underlying mechanism is identical. However, compounded medications are not FDA-approved and have not been reviewed for safety, effectiveness, or quality. They should only be obtained through licensed pharmacies working with qualified physicians who can ensure proper formulation and dosing.
Can I switch from one GLP-1 medication to another?
Yes, patients can transition between different GLP-1 protocols under physician supervision. Your provider will create a transition plan that accounts for the different pharmacokinetics of each medication. Some patients switch due to tolerability, access, or seeking enhanced efficacy. Clinical data suggests that switching is generally well-tolerated when done with appropriate washout periods or dose adjustments.
What happens to weight loss if I stop taking a GLP-1 receptor agonist?
Clinical evidence indicates that weight regain commonly occurs when GLP-1 medications are discontinued, though the extent varies among individuals. The SURMOUNT-MAINTAIN trial showed that participants who stopped tirzepatide regained significant weight compared to those who continued (Horn et al., 2026). This underscores the importance of viewing these protocols as long-term metabolic support rather than short-term interventions.
References
Yao H, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024. PMID: 38286487.
Liu Y, et al. The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. Am J Clin Nutr. 2023. PMID: 37661106.
Shi Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2024. PMID: 38582569.
Horn D, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2026. PMID: 42119587.
Zhang S, et al. Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis. Diabetes Technol Ther. 2025. PMID: 39911047.
Shi Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2022. PMID: 34895470.
Learn more about your options:
Source Studies:
Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body ... — BMJ (Clinical research ed.) (2024)
The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in ... — The American journal of clinical nutrition (2023)
Pharmacotherapy for adults with overweight and obesity: a systematic review and ... — Lancet (London, England) (2024)
Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.
Treatments are prescribed at provider discretion. Individual results may vary.